Further, we observed that Usp22 targeted inhibition synergized with anti–PD-1 treatment leading to a complete rejection of orthotopic 4T1 TNBC, MC38 colon cancer and RM1 prostate cancer (Supplemental Figure 5, A–F). Here, USP22 is linked to prostate carcinoma.